110 related articles for article (PubMed ID: 3145998)
1. [Improvement in anti-hemophilic preparations and its problems. 7. Present status and future aspect of anti-hemophilic preparations].
Kamiya T
Rinsho Ketsueki; 1988 May; 29(5):666-70. PubMed ID: 3145998
[No Abstract] [Full Text] [Related]
2. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
Ikematsu S; Yorifuji H; Arai M; Fukutake K
Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
[No Abstract] [Full Text] [Related]
3. [Improvement in anti-hemophilic preparations and its problems. 3. Treatment of hemophilia patients with inhibitors; induction of immune tolerance by a low or intermediate dose regimen].
Iizuka A
Rinsho Ketsueki; 1988 May; 29(5):640-8. PubMed ID: 3145995
[No Abstract] [Full Text] [Related]
4. [Virus in hemophilia: current status and future perspectives].
Aguilar C; Félix Lucía J
Sangre (Barc); 1996 Apr; 41(2):141-5. PubMed ID: 9045355
[No Abstract] [Full Text] [Related]
5. Blood safety and the choice of anti-hemophilic factor concentrate.
Janco RL
Pediatr Blood Cancer; 2007 Jan; 48(1):117. PubMed ID: 17063470
[No Abstract] [Full Text] [Related]
6. [Improvement in anti-hemophilic preparations and its problems. 4. Factor VIII preparation (RCG-5) with intermediate purity and potency].
Yoshioka A
Rinsho Ketsueki; 1988 May; 29(5):649-54. PubMed ID: 3145996
[No Abstract] [Full Text] [Related]
7. Correlation of antibodies to LAV/HTLV III in hemophiliacs with the use of virus-inactivated clotting factors.
Dietz B; Klose HJ; Gürtler L; Eberle J; Deinhardt F; Köhler-Vajta K; Peller P
Thromb Haemost; 1986 Aug; 56(1):50-2. PubMed ID: 3095947
[TBL] [Abstract][Full Text] [Related]
8. [Technic of obtaining the antihemophilic factors VIII and IX and their clinical application].
Triginer J; Vila M; Vicente Arangüena P
Sangre (Barc); 1979; 24(5-C):937-41. PubMed ID: 121169
[No Abstract] [Full Text] [Related]
9. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
Schimpf K; Schwarz P; Kunschak M
Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
[No Abstract] [Full Text] [Related]
10. Modern treatment of hemophilia: from the shadows towards the light.
Mannucci PM
Thromb Haemost; 1993 Jul; 70(1):17-23. PubMed ID: 8236096
[No Abstract] [Full Text] [Related]
11. [Improvement in anti-hemophilic preparations and its problems. 5. Stability and oral administration of factor VIII and IX concentrates].
Oguma Y; Shimizu K; Sakuragawa N
Rinsho Ketsueki; 1988 May; 29(5):655-61. PubMed ID: 3145997
[No Abstract] [Full Text] [Related]
12. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].
Pollmann H
Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():80-3. PubMed ID: 8000261
[TBL] [Abstract][Full Text] [Related]
13. Physiologic considerations in the management of hemophilia.
Briggs DK
Pathobiol Annu; 1971; 1():205-14. PubMed ID: 4950380
[No Abstract] [Full Text] [Related]
14. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
[TBL] [Abstract][Full Text] [Related]
15. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C and pasteurised factor VIII and IX concentrates.
Klarmann D; Kreuz W; Auerswald G; Auberger K; Rabenau H; Gürtler L; Roggendorf M
Thromb Haemost; 1995 Apr; 73(4):736-7. PubMed ID: 7495095
[No Abstract] [Full Text] [Related]
17. Factor VIII:C purified from plasma via monoclonal antibodies: human studies.
Levine PH
Semin Hematol; 1988 Apr; 25(2 Suppl 1):38-41. PubMed ID: 2968653
[No Abstract] [Full Text] [Related]
18. Current status and trends in the treatment of hemophilic patients with inhibitors.
Bloom AL
Prog Clin Biol Res; 1981; 72():123-38. PubMed ID: 6801682
[No Abstract] [Full Text] [Related]
19. Monoclonal antibodies to human procoagulant factor VIII.
Rotblat F; Goodall AH; O'Brien DP; Rawlings E; Middleton S; Tuddenham EG
J Lab Clin Med; 1983 May; 101(5):736-46. PubMed ID: 6403638
[TBL] [Abstract][Full Text] [Related]
20. [Cellular immunology status in 5 hemophilic patients with inhibitors subjected to massive therapy with factor VIII concentrate].
Aznar JA; Jorquera JI; González Molina A; Carbonell F; Trenor A; Sánchez Cuenca JM; de Andrés R
Sangre (Barc); 1983; 28(5):663-4. PubMed ID: 6420915
[No Abstract] [Full Text] [Related]
[Next] [New Search]
